TransCode Therapeutics, Inc., (RNAZ): Price and Financial Metrics
RNAZ Price/Volume Stats
Current price | $10.36 | 52-week high | $66.33 |
Prev. close | $10.66 | 52-week low | $2.66 |
Day low | $10.10 | Volume | 134,700 |
Day high | $10.56 | Avg. volume | 3,291,350 |
50-day MA | $6.32 | Dividend yield | N/A |
200-day MA | $17.84 | Market Cap | 7.21M |
RNAZ Stock Price Chart Interactive Chart >
TransCode Therapeutics, Inc., (RNAZ) Company Bio
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts.
RNAZ Price Returns
1-mo | 209.25% |
3-mo | -4.87% |
6-mo | 14.16% |
1-year | -53.76% |
3-year | -99.98% |
5-year | N/A |
YTD | 207.42% |
2024 | -98.45% |
2023 | -98.78% |
2022 | -73.50% |
2021 | N/A |
2020 | N/A |
Loading social stream, please wait...